Histone deacetylase inhibitors as immunomodulators in cancer therapeutics

Li Shen, Ashley Orillion, Roberto Pili

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

HDAC inhibitors (HDACIs) are anticancer agents being developed in preclinical and clinical settings due to their capacity to modulate gene expression involved in cell growth, differentiation and apoptosis, through modification of both chromatin histone and nonhistone proteins. Most HDACIs in clinical development have cytotoxic or cytostatic properties and their direct inhibitory effects on tumor cells are well documented. Numerous studies have revealed that HDACIs have potent immunomodulatory activity in tumor-bearing animals and cancer patients, providing guidance to apply these agents in cancer immunotherapies. Here, we summarize recent reports addressing the effects of HDACIs on tumor cell immunogenicity, and on different components of the host immune system. In addition, we discuss the complexity of the immunomodulatory activity of these agents, which depends on the class specificity of the HDACIs, different experimental settings and the target immune cell populations.

Original languageEnglish (US)
Pages (from-to)415-428
Number of pages14
JournalEpigenomics
Volume8
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Histone Deacetylase Inhibitors
Immunologic Factors
Neoplasms
Therapeutics
Cytostatic Agents
Antineoplastic Agents
Histones
Immunotherapy
Chromatin
Cell Differentiation
Immune System
Apoptosis
Gene Expression
Growth
Population
Proteins

Keywords

  • antigen-presenting cells
  • cancer immunotherapy
  • Foxp3
  • histone deacetylase inhibitor
  • immunomodulation
  • inflammatory cytokines
  • myeloid-derived suppressor cells
  • Tregs
  • tumor associated macrophage

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. / Shen, Li; Orillion, Ashley; Pili, Roberto.

In: Epigenomics, Vol. 8, No. 3, 01.03.2016, p. 415-428.

Research output: Contribution to journalReview article

Shen, Li ; Orillion, Ashley ; Pili, Roberto. / Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. In: Epigenomics. 2016 ; Vol. 8, No. 3. pp. 415-428.
@article{5bf6811510ec40d1bc333224ad4126ae,
title = "Histone deacetylase inhibitors as immunomodulators in cancer therapeutics",
abstract = "HDAC inhibitors (HDACIs) are anticancer agents being developed in preclinical and clinical settings due to their capacity to modulate gene expression involved in cell growth, differentiation and apoptosis, through modification of both chromatin histone and nonhistone proteins. Most HDACIs in clinical development have cytotoxic or cytostatic properties and their direct inhibitory effects on tumor cells are well documented. Numerous studies have revealed that HDACIs have potent immunomodulatory activity in tumor-bearing animals and cancer patients, providing guidance to apply these agents in cancer immunotherapies. Here, we summarize recent reports addressing the effects of HDACIs on tumor cell immunogenicity, and on different components of the host immune system. In addition, we discuss the complexity of the immunomodulatory activity of these agents, which depends on the class specificity of the HDACIs, different experimental settings and the target immune cell populations.",
keywords = "antigen-presenting cells, cancer immunotherapy, Foxp3, histone deacetylase inhibitor, immunomodulation, inflammatory cytokines, myeloid-derived suppressor cells, Tregs, tumor associated macrophage",
author = "Li Shen and Ashley Orillion and Roberto Pili",
year = "2016",
month = "3",
day = "1",
doi = "10.2217/epi.15.118",
language = "English (US)",
volume = "8",
pages = "415--428",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Histone deacetylase inhibitors as immunomodulators in cancer therapeutics

AU - Shen, Li

AU - Orillion, Ashley

AU - Pili, Roberto

PY - 2016/3/1

Y1 - 2016/3/1

N2 - HDAC inhibitors (HDACIs) are anticancer agents being developed in preclinical and clinical settings due to their capacity to modulate gene expression involved in cell growth, differentiation and apoptosis, through modification of both chromatin histone and nonhistone proteins. Most HDACIs in clinical development have cytotoxic or cytostatic properties and their direct inhibitory effects on tumor cells are well documented. Numerous studies have revealed that HDACIs have potent immunomodulatory activity in tumor-bearing animals and cancer patients, providing guidance to apply these agents in cancer immunotherapies. Here, we summarize recent reports addressing the effects of HDACIs on tumor cell immunogenicity, and on different components of the host immune system. In addition, we discuss the complexity of the immunomodulatory activity of these agents, which depends on the class specificity of the HDACIs, different experimental settings and the target immune cell populations.

AB - HDAC inhibitors (HDACIs) are anticancer agents being developed in preclinical and clinical settings due to their capacity to modulate gene expression involved in cell growth, differentiation and apoptosis, through modification of both chromatin histone and nonhistone proteins. Most HDACIs in clinical development have cytotoxic or cytostatic properties and their direct inhibitory effects on tumor cells are well documented. Numerous studies have revealed that HDACIs have potent immunomodulatory activity in tumor-bearing animals and cancer patients, providing guidance to apply these agents in cancer immunotherapies. Here, we summarize recent reports addressing the effects of HDACIs on tumor cell immunogenicity, and on different components of the host immune system. In addition, we discuss the complexity of the immunomodulatory activity of these agents, which depends on the class specificity of the HDACIs, different experimental settings and the target immune cell populations.

KW - antigen-presenting cells

KW - cancer immunotherapy

KW - Foxp3

KW - histone deacetylase inhibitor

KW - immunomodulation

KW - inflammatory cytokines

KW - myeloid-derived suppressor cells

KW - Tregs

KW - tumor associated macrophage

UR - http://www.scopus.com/inward/record.url?scp=84962619632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962619632&partnerID=8YFLogxK

U2 - 10.2217/epi.15.118

DO - 10.2217/epi.15.118

M3 - Review article

C2 - 26950532

AN - SCOPUS:84962619632

VL - 8

SP - 415

EP - 428

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 3

ER -